Alnylam Pharmace. buy William Blair
Start price
08.04.24
/
50%
€143.80
Target price
08.04.25
-
Performance (%)
-4.35%
Price
29.04.24
€137.55
Summary
This prediction is currently active. With a performance of -4.35%, the BUY prediction for Alnylam Pharmace. by William_Blair is down slightly. This prediction currently runs until 08.04.25. The prediction end date can be changed by William_Blair at any time. William_Blair has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w |
|---|---|
| Alnylam Pharmace. | 0.438% |
| iShares Core DAX® | 0.961% |
| iShares Nasdaq 100 | 2.626% |
| iShares Nikkei 225® | 0.217% |
| iShares S&P 500 | 1.540% |
Comments by William_Blair for this prediction
In the thread Alnylam Pharmace. diskutieren
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "outperform" rating re-affirmed by analysts at William Blair.
Ratings data for ALNY provided by MarketBeat